Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.

Abstract

OBJECTIVE:

Cannabidiol (CBD) has been approved by the US Food and Drug Administration (FDA) to treat intractable childhood epilepsies, such as Dravet syndrome and Lennox-Gastaut syndrome. However, the intrinsic anticonvulsant activity of CBD has been questioned due to a pharmacokinetic interaction between CBD and a first-line medication, clobazam. This recognized interaction has led to speculation that the anticonvulsant efficacy of CBD may simply reflect CBD augmenting clobazam exposure. The present study aimed to address the nature of the interaction between CBD and clobazam.

METHODS:

We examined whether CBD inhibits human CYP3A4 and CYP2C19 mediated metabolism of clobazam and N-desmethylclobazam (N-CLB), respectively, and performed studies assessing the effects of CBD on brain and plasma pharmacokinetics of clobazam in mice. We then used the Scn1a+/- mouse model of Dravet syndrome to examine how CBD and clobazam interact. We compared anticonvulsant effects of CBD-clobazam combination therapy to monotherapy against thermally-induced seizures, spontaneous seizures and mortality in Scn1a+/- mice. In addition, we used Xenopus oocytes expressing γ-aminobutyric acid (GABA)A receptors to investigate the activity of GABAA receptors when treated with CBD and clobazam together.

RESULTS:

CBD potently inhibited CYP3A4 mediated metabolism of clobazam and CYP2C19 mediated metabolism of N-CLB. Combination CBD-clobazam treatment resulted in greater anticonvulsant efficacy in Scn1a+/- mice, but only when an anticonvulsant dose of CBD was used. It is important to note that a sub-anticonvulsant dose of CBD did not promote greater anticonvulsant effects despite increasing plasma clobazam concentrations. In addition, we delineated a novel pharmacodynamic mechanism where CBD and clobazam together enhanced inhibitory GABAA receptor activation.

SIGNIFICANCE:

Our study highlights the involvement of both pharmacodynamic and pharmacokinetic interactions between CBD and clobazam that may contribute to its efficacy in Dravet syndrome.

• Authors: Lyndsey L Anderson, Nathan L Absalom, Sarah V Abelev, Ivan K Low, Peter T Doohan, Lewis J Martin, Mary Chebib, Iain S McGregor, Jonathon C Arnold
• Journal: Epilepsia (Epilepsia) Vol. 60 Issue 11 Pg. 2224-2234 (11 2019) ISSN: 1528-1167 [Electronic] United States
• PMID: 31625159 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2019 The Authors. Epilepsia published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy.

Chemical References

• Anticonvulsants
• NAV1.1 Voltage-Gated Sodium Channel
• Scn1a protein, mouse
• Cannabidiol
• Clobazam

Topics

• Animals
• Anticonvulsants (administration & dosage, pharmacokinetics)
• Cannabidiol (administration & dosage, pharmacokinetics)
• Clobazam (administration & dosage, pharmacokinetics)
• Dose-Response Relationship, Drug
• Drug Evaluation, Preclinical (methods)
• Drug Interactions (physiology)
• Drug Therapy, Combination
• Epilepsies, Myoclonic (drug therapy, genetics, metabolism)
• Humans
• Mice
• Mice, Transgenic
• NAV1.1 Voltage-Gated Sodium Channel (genetics)